This site is intended for Healthcare professionals only.
×

Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer


Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.

ZURICH: Novartis has secured the U.S. Food and Drug Administration’s Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.

Also Read: Fight for Vidagliptin: Natco goes to court against Novartis

Novartis is aiming to win approval for oral capmatinib as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC), a form of the disease for which there are no targeted therapies now, the Basel-based company said on Friday.

Also Read: Novartis sees gene, cell therapy reaching up to 15pc of total revenue in midterm


Source: Reuters
0 comment(s) on Novartis wins USFDA breakthrough tag for Capmatinib to treat lung cancer

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted